Proton Pump Inhibitors - CME Conferences
Proton Pump Inhibitors - CME Conferences Proton Pump Inhibitors - CME Conferences
6 th Annual Primary Care Spring Conference Thursday, April 12, 2012 April 20, 2011 —A report from the IMS Institute for Healthcare Informatics • For Americans covered by insurance, Medicare, or Medicaid, the average copayment for a prescription was $10.73 -- down a bit from 2009 due to increased use of generic drugs. • The average co-payment for branded drugs for which generic alternatives were available jumped 6% to $22.73. In 2010 the 10 drugs on which we spent the most were: 1. Lipitor (atorvastatin)-- $7.2 billion (11-2011) 2. Nexium (esomeprazole)-- $6.3 billion 3. Plavix (clopidogrel) -- $6.1 billion (5-2012) 4. Advair Diskus (salmeterol/fluticazone)-- $4.7 billion 5. Abilify (aripiprazole)-- $4.6 billion 6. Seroquel (quetiapine)-- $4.4 billion (3-2012) 7. Singulair (montelukast)-- $4.1 billion (8-2012) 8. Crestor (rosuvastatin)-- $3.8 billion 9. Actos (pioglitazone)-- $3.5 billion (8-2012) 10. Epogen (epoetin alfa)-- $3.3 billion 2010 IMS report: Wayne Weart, Pharm D Cost Effective Rx
6 th Annual Primary Care Spring Conference Thursday, April 12, 2012 Additional Opportunities for Generic Savings in 2011-2012 • Levofloxacin – Levaquin 6-2011 • Olanzapine – Zyprexa 10-2011 • Atorvastatin/amlodipine – Caduet 11-2011 • Escitalopram – Lexapro 2-2012 • Ibandronate – Boniva 3-2012 • Sildenafil – Viagra 3-2012 • Irbesartan – Avapro 3-2012 • Entanercept – Enbrel 8-2012 • Valsartan – Diovan 9-2012 • Valsartan/amlodipine – Exforge 9-2012 • Ziprasidone – Geodon 9-2012 • Candesartan – Atacand – 12-2012 • Rizatriptan – Maxalt 12-2012 April 20, 2011 —A report from the IMS Institute for Healthcare Informatics • The IMS reports that Americans spent $307 billion on prescription drugs in 2010 • Brands that lost their protection from generic competition led to $12.6 billion less spending in 2010 than in 2009. • The price increase for drugs without generic competition led to $16.6 billion more spending in 2010 than in 2009. • Drug companies offered $4.5 billion in rebates to assist patients with the high cost of brand name drugs for which there was no generic alternative. 2010 IMS report: Wayne Weart, Pharm D Cost Effective Rx
- Page 1 and 2: 6 th Annual Primary Care Spring Con
- Page 3 and 4: 6 th Annual Primary Care Spring Con
- Page 5 and 6: 6 th Annual Primary Care Spring Con
- Page 7: 6 th Annual Primary Care Spring Con
- Page 11 and 12: 6 th Annual Primary Care Spring Con
- Page 13 and 14: 6 th Annual Primary Care Spring Con
- Page 15 and 16: 6 th Annual Primary Care Spring Con
- Page 17 and 18: 6 th Annual Primary Care Spring Con
- Page 19 and 20: 6 th Annual Primary Care Spring Con
- Page 21 and 22: 6 th Annual Primary Care Spring Con
- Page 23 and 24: 6 th Annual Primary Care Spring Con
- Page 25 and 26: 6 th Annual Primary Care Spring Con
- Page 27 and 28: 6 th Annual Primary Care Spring Con
- Page 29 and 30: 6 th Annual Primary Care Spring Con
- Page 31 and 32: 6 th Annual Primary Care Spring Con
- Page 33 and 34: 6 th Annual Primary Care Spring Con
- Page 35 and 36: 6 th Annual Primary Care Spring Con
- Page 37 and 38: 6 th Annual Primary Care Spring Con
- Page 39 and 40: 6 th Annual Primary Care Spring Con
- Page 41 and 42: 6 th Annual Primary Care Spring Con
- Page 43 and 44: 6 th Annual Primary Care Spring Con
- Page 45 and 46: 6 th Annual Primary Care Spring Con
- Page 47 and 48: 6 th Annual Primary Care Spring Con
- Page 49 and 50: 6 th Annual Primary Care Spring Con
- Page 51 and 52: 6 th Annual Primary Care Spring Con
- Page 53 and 54: 6 th Annual Primary Care Spring Con
6 th Annual Primary Care Spring Conference Thursday, April 12, 2012<br />
Additional Opportunities for Generic<br />
Savings in 2011-2012<br />
• Levofloxacin – Levaquin 6-2011<br />
• Olanzapine – Zyprexa 10-2011<br />
• Atorvastatin/amlodipine – Caduet 11-2011<br />
• Escitalopram – Lexapro 2-2012<br />
• Ibandronate – Boniva 3-2012<br />
• Sildenafil – Viagra 3-2012<br />
• Irbesartan – Avapro 3-2012<br />
• Entanercept – Enbrel 8-2012<br />
• Valsartan – Diovan 9-2012<br />
• Valsartan/amlodipine – Exforge 9-2012<br />
• Ziprasidone – Geodon 9-2012<br />
• Candesartan – Atacand – 12-2012<br />
• Rizatriptan – Maxalt 12-2012<br />
April 20, 2011 —A report from the IMS<br />
Institute for Healthcare Informatics<br />
• The IMS reports that Americans spent $307<br />
billion on prescription drugs in 2010<br />
• Brands that lost their protection from generic<br />
competition led to $12.6 billion less spending in<br />
2010 than in 2009.<br />
• The price increase for drugs without generic<br />
competition led to $16.6 billion more spending in<br />
2010 than in 2009.<br />
• Drug companies offered $4.5 billion in rebates to<br />
assist patients with the high cost of brand name<br />
drugs for which there was no generic alternative.<br />
2010 IMS report:<br />
Wayne Weart, Pharm D<br />
Cost Effective Rx
Change language